A Dose Finding and Efficacy Study of the Tumour Targeting Human 131I-F16SIP Monoclonal Antibody in Patients With Cancer

NCT01240720 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: 131I-F16SIP Radioimmunotherapy (RIT)

Sponsor

Philogen S.p.A.

Collaborators

[object Object]